Steris (STE) Cash from Financing Activities (2018 - 2026)
Steris' (STE) quarterly Cash from Financing Activities came in at -$97.9 million in Q1 2026, up 45.03% year-on-year from -$67.5 million in Q1 2025, and little changed quarter-over-quarter from -$98.0 million in Q4 2025.
Steris (STE) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Steris' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$97.9 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 45.03% year-over-year to -$97.9 million in Q1 2026; TTM through Mar 2026 was -$568.2 million, a 63.86% increase from a year earlier, with the FY2026 full-year figure at -$568.2 million, up 63.86% from the prior year.
- Cash from Financing Activities steadied at -$97.9 million in Q1 2026 per STE's latest filing, from -$98.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $470.2 million in Q3 2023 and bottomed at -$998.9 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is -$178.1 million (2025), against an average of -$176.4 million.
- Across the five-year window, Cash from Financing Activities surged 1146.13% in 2023 and plunged 367.57% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at -$120.4 million in 2022, then slumped by 64.43% to -$198.0 million in 2023, then declined by 8.29% to -$214.4 million in 2024, then surged by 54.29% to -$98.0 million in 2025, then rose by 0.1% to -$97.9 million in 2026.
- Per Business Quant, the three latest STE Cash from Financing Activities figures stand at -$97.9 million (Q1 2026), -$98.0 million (Q4 2025), and -$159.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Steris | 20.59 Bn | 20.16 Bn | 697.10 Mn | -97.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.90 Mn |
| Mar 31, 2026 | -97.90 Mn |
| Dec 31, 2025 | -98.00 Mn |
| Dec 31, 2025 | -98.00 Mn |
| Sep 30, 2025 | -159.20 Mn |
| Sep 30, 2025 | -159.20 Mn |
| Jun 30, 2025 | -213.10 Mn |
| Jun 30, 2025 | -213.10 Mn |
| Mar 31, 2025 | -178.10 Mn |
| Mar 31, 2025 | -178.10 Mn |
| Dec 31, 2024 | -214.40 Mn |
| Dec 31, 2024 | -214.40 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Jun 30, 2024 | -998.90 Mn |
| Jun 30, 2024 | -998.90 Mn |
| Mar 31, 2024 | -143.78 Mn |
| Mar 31, 2024 | -143.78 Mn |
| Dec 31, 2023 | -197.99 Mn |
| Dec 31, 2023 | -197.99 Mn |